Curasight A/S has announced the prioritization of brain cancer as the lead indication for its uTREAT radioligand therapy platform. This decision follows a positive Q3 2024 interim report, highlighting key milestones in the company's clinical development programs and strategic partnerships.
Brain Cancer Focus for uTREAT
The selection of brain cancer as the primary focus for uTREAT is based on the significant unmet medical need and the potential of the urokinase-type plasminogen activator receptor (uPAR) as a therapeutic target. Curasight is currently enrolling patients in a Phase II trial evaluating uTRACE, a uPAR-PET imaging agent, in brain cancer. The trial aims to improve diagnostic accuracy and guide treatment decisions.
Financial Update and Business Development
Curasight's Q3 2024 report indicates a gross loss of kDKK -6,135 and an operating loss of kDKK -8,099. Despite these losses, the company's financial position has been bolstered by a heavily oversubscribed rights issue, extending the cash runway into the latter half of 2025. According to CEO Ulrich Krasilnikoff, Curasight is actively pursuing business development opportunities with industry players to further expand the application of its theranostic platform.
Ongoing Clinical Programs
In addition to the brain cancer program, Curasight is advancing its uTRACE imaging agent in prostate cancer, with the first patient enrolled in a Phase II trial. The company also continues its collaboration with Curium, receiving a second milestone payment under the partnership. These ongoing clinical programs and partnerships underscore Curasight's commitment to developing innovative radiopharmaceutical solutions for cancer diagnosis and therapy.
About Curasight
Curasight is a clinical development company based in Copenhagen, Denmark, focused on exploiting the uPAR theranostic platform (uTRACE® and uTREAT®). Their technology aims to improve cancer diagnosis and treatment by targeting the urokinase-type plasminogen activator receptor (uPAR).
